NASH/MASH Treatment Market to Surpass USD 31.76 Billion by 2033 as First-in-Class Drugs Redefine Fatty Liver Disease Management | According to DataM Intelligence

According to DataM Intelligence, the NASH/MASH Treatment Market Size was valued at USD 7.87 billion in 2024 and is projected ...
Asianet Newsable on MSN

Madrigal Pharma Stock Sees Buyout Hype – Retail Predicts ‘Huge’ Deal On Liver Disease Drug Momentum

Fresh analyst target hikes followed new two-year clinical data showing sustained improvements in key liver-health measures.
STAT

Madrigal experimental drug delivers strong results in fatty liver disease known as NASH

Madrigal Pharmaceuticals said Monday that its experimental treatment for fatty liver disease improved liver biopsies by two different measures in a study of 950 patients, reducing the fat deposits and ...

DataM Intelligence 4 Market Research LLP: NASH/MASH Treatment Market to Surpass USD 31.76 Billion by 2033 as First-in-Class Drugs Redefine Fatty Liver Disease Management ...

According to DataM Intelligence, the NASH/MASH Treatment Market Size was valued at USD 7.87 billion in 2024 and is projected to ...